Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
about
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.Some Pharmacodynamic Aspects of Cefepime.Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysisProlonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae.Management of aminoglycosides in the intensive care unit.In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
P2860
Q33508985-1FD5DE3C-407A-4B6E-974C-57BD2D463A31Q33676227-D5B27DBC-E68E-479A-8E1F-2C0AF9188F8EQ35666617-1BC6ADD8-2B2E-4088-B193-0FC44967D693Q36129540-CB9E7091-B948-4A38-9E01-430510883F6FQ37335646-A19728B6-F1E5-4221-A417-35497A7BCF64Q38073197-7B72470C-FF90-464E-9CA2-71A6D7660BADQ41840120-43C1962F-8311-4A00-80D5-072717E19754Q42908869-D32F9CE3-0168-406F-A0EB-9EAB0AC1D5ABQ42947141-1680B8B6-2F1F-44D9-A9B2-18487A11194BQ43516275-CE600756-CB0A-41E5-BBDA-1CD975097B0A
P2860
Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Comparison of 2002-2006 OPTAMA ...... s on gram-negative resistance.
@en
Comparison of 2002-2006 OPTAMA ...... s on gram-negative resistance.
@nl
type
label
Comparison of 2002-2006 OPTAMA ...... s on gram-negative resistance.
@en
Comparison of 2002-2006 OPTAMA ...... s on gram-negative resistance.
@nl
prefLabel
Comparison of 2002-2006 OPTAMA ...... s on gram-negative resistance.
@en
Comparison of 2002-2006 OPTAMA ...... s on gram-negative resistance.
@nl
P2093
P2860
P356
P1476
Comparison of 2002-2006 OPTAMA ...... s on gram-negative resistance.
@en
P2093
David P Nicolau
Jared L Crandon
Joseph L Kuti
Ronald N Jones
P2860
P304
P356
10.1345/APH.1L473
P407
P577
2009-02-03T00:00:00Z